<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185974</url>
  </required_header>
  <id_info>
    <org_study_id>RADONK-CARE-2018</org_study_id>
    <nct_id>NCT04185974</nct_id>
  </id_info>
  <brief_title>Carbon Ion Re-Radiotherapy in Patients With Recurrent or Progressive Locally Advanced Head-and-Neck Cancer</brief_title>
  <acronym>CARE</acronym>
  <official_title>Carbon Ion Re-Radiotherapy in Patients With Recurrent or Progressive Locally Advanced Head-and-Neck Cancer: A Phase-II Study to Evaluate Toxicity and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After multimodal therapy of head-and-neck tumors, patients often develop local recurrence,&#xD;
      locally progressive disease or second primary tumors. In this highly pre-treated patient&#xD;
      cohort, therapeutic options are limited. Patients that are not candidates for salvage surgery&#xD;
      may benefit from re-irradiation. Despite recent technical advances, re-irradiation is&#xD;
      associated with severe side effects. Carbon ion Re-Radiotherapy (reCIRT) has shown&#xD;
      encouraging results in retrospective analyses with moderate toxicity.&#xD;
&#xD;
      In the current Phase-II CARE-trial, reCIRT and conventional photon re-irradiation in patients&#xD;
      with recurrent or progressive locally advanced head-and-neck cancer will be assessed&#xD;
      regarding toxicity/ safety, local progression-free survival, overall survival and&#xD;
      quality-of-life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of head-and-neck cancer worldwide amounts to around 550.000 cases per year,&#xD;
      with male patients affected significantly more often. Common risk factors are smoking,&#xD;
      alcohol, viral infections, immunodeficiency or genetic factors. Locally advanced&#xD;
      head-and-neck tumors can lead to severe symptoms such as dysphagia, cachexia and tumor pain&#xD;
      with a significant decrease of the quality-of-life. The prognosis depends on multiple factors&#xD;
      such as TNM-staging, tumor volume, histology, general condition, age and smoking. Further&#xD;
      risk factors are positive resection margins, extracapsular extension and perineural invasion.&#xD;
      While metastatic spread significantly decreases overall survival, the life-limiting problem&#xD;
      in patients with head-and-neck cancer is locally invasive and destructive tumor growth&#xD;
      leading to a decrease of the performance status and quality of life. After multimodal therapy&#xD;
      of locally advanced head-and-neck tumors, around 30 - 50% of patients will develop local&#xD;
      recurrence or locally progressive disease and up to 8% of patients with HNSCC will develop a&#xD;
      second primary tumor in the head-and-neck .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of carbon ion re-irradiation</measure>
    <time_frame>6 month</time_frame>
    <description>the rate of patients with an acute/subacute toxicity CTCAE v5.0 ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>toxicity of carbon ion re-irradiation</measure>
    <time_frame>6 month</time_frame>
    <description>the rate of patients with an acute/subacute toxicity CTCAE v5.0 ≥ grade 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>12 month</time_frame>
    <description>Local progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 month</time_frame>
    <description>within 12 month after re-irradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on EORTC QLQ C30 Quality of life questionaire</measure>
    <time_frame>within 12 month after re-irradiation</time_frame>
    <description>EORTC (European Organization for Research and. Treatment of Cancer) QLQ (quality of life questionnaire) C30, score 1-6, high score means worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on EORTC QLQ H&amp;N35 Quality of life questionaire</measure>
    <time_frame>within 12 month after re-irradiation</time_frame>
    <description>QLQ (quality of life questionnaire)-H&amp;N (Head and neck) 35, score 1-6, high score means worse outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Locally Advanced Head-and-Neck Cancer</condition>
  <arm_group>
    <arm_group_label>C12 irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of Safety and Toxicity of C12 ion reirradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Photon irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluation of Safety and Toxicity of photon re-irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>C12 re-irradiation</intervention_name>
    <description>51 Gy(RBE) or 54 Gy</description>
    <arm_group_label>C12 irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Photon re-irradiation</intervention_name>
    <description>54 Gy(RBE) or 60 Gy</description>
    <arm_group_label>Photon irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Locally recurrent / progressive head-and-neck cancer after initial radiation therapy&#xD;
&#xD;
          -  Microscopic or macroscopic tumor after salvage surgery&#xD;
&#xD;
          -  Indication for re-irradiation&#xD;
&#xD;
          -  Completed wound healing after surgical intervention&#xD;
&#xD;
          -  Karnofsky-Performance-Score ≥ 60&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Written informed consent (must be available before enrolment in the trial)&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of the trial&#xD;
&#xD;
          -  For women with childbearing potential, (and men) adequate contraception&#xD;
&#xD;
          -  Submission of previous radiotherapy records&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Re-irradiation of malignancy in the larynx&#xD;
&#xD;
          -  Diagnosed plasmocytoma, sarcoma or chordoma&#xD;
&#xD;
          -  Previous re-irradiation in-field&#xD;
&#xD;
          -  Time interval &lt; 6 months after initial radiotherapy&#xD;
&#xD;
          -  Distant metastases (except pulmonary metastases)&#xD;
&#xD;
          -  Patients who have not recovered from acute toxicities of prior therapies&#xD;
&#xD;
          -  Refusal of the patients to take part in the study&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Known carcinoma &lt;5 years ago (excluding Carcinoma in situ of the cervix, basal cell&#xD;
             carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment&#xD;
             interfering with study therapy&#xD;
&#xD;
          -  Participation in another clinical study or observation period of competing trials,&#xD;
             respectively&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sebastian Adeberg, PD</last_name>
    <phone>49 622156</phone>
    <phone_ext>35754</phone_ext>
    <email>sebastian.adeberg@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hommertgen Adriane, PhD</last_name>
    <phone>49 622156</phone>
    <phone_ext>34091</phone_ext>
    <email>adriane.hommertgen@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Heidelberg, Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Debus, Prof. Dr.</last_name>
      <phone>+49-6221-56</phone>
      <phone_ext>8202</phone_ext>
      <email>juergen.debus@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Adriane Hommertgen</last_name>
      <phone>+49-6221-56</phone>
      <phone_ext>34091</phone_ext>
      <email>adriane.hommertgen@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Head of department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

